Abstract
Background
Epidermal growth factor receptor (EGFR) mutation testing is recommended for selecting patients with non-squamous non-small cell lung cancer (NSCLC) for EGFR tyrosine kinase inhibitor drug treatment.
Objective
The objective of this article was to systematically review available evidence on the utilisation and determinants of EGFR mutation testing of patients with NSCLC in routine clinical practice.
Patients and Methods
Searches were made of five electronic databases (Web of Science, MEDLINE [Ovid], Science Direct, EMBASE and Scopus), bibliographies of relevant articles, studies that cited included studies and relevant cancer websites. Studies were included if they: (1) reported the rate of uptake of EGFR testing in patients with NSCLC; (2) were conducted in routine clinical practice settings; (3) were published in English prior to July 2017; and (4) had full text available. Studies were appraised using the STROBE and the National Institutes of Health (National Heart, Lung and Blood Institute) checklists.
Results
Eighteen eligible studies were identified for this systematic review, published between 2011 and 2017, from the USA (n = 7), Canada (n = 2), Republic of Korea (n = 2), Norway (n = 1), Sweden (n = 1), Germany (n = 1), Spain (n = 1), New Zealand (n = 1), China (n = 1) and multiple countries from the Asia–Pacific region (n = 1). Overall, testing for EGFR mutations was undertaken in 16,146 of 52,257 study patients (31%), although testing rates varied widely between different studies (from 7.8% to 78.3%). Single institution retrospective audits reported higher rates of testing (median 65.7%, range 31.3–78.3%) than population-based retrospective cohort analyses (median 23%, range 11–69%) and multi-institutional cross-sectional practitioner surveys (median 19.8%, range 7.8–31.8%). Nine studies reported increasing rates of testing over the study period but maximum testing rates remained less than 75% in most studies. Factors associated with higher testing uptake rates included: female sex; younger age; former/no smoking; advanced stage of lung cancer; adenocarcinoma histology; better mobility; radiation therapy; available tissue specimen; and private insurance. Among 16,146 tested patients, EGFR mutations were detected in 4328 patients (26.8%). However, estimates of mutation prevalence were biased by incomplete and selective testing in many studies.
Conclusions
The uptake of EGFR mutation testing of patients with NSCLC is suboptimal in many parts of the world. Incomplete uptake of testing is fuelled by selective testing referral practices, sample limitations, and funding constraints.
Similar content being viewed by others
References
Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1):8. https://doi.org/10.5334/aogh.2419.
Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther. 2017;102(5):757–64.
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai C, et al. Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595–605.
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–59.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, Version 6. J Natl Compr Canc Netw. 2015;13(5):515–24.
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr K, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl_3):iii27–39.
Choi Y, Sun J, Cho J, Rampal S, Han J, Parasuraman B, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS ONE. 2013;8(2):e56011.
Gutierrez ME, Choi K, Lanman RB, Licitra EJ, Skrzypczak SM, Pe Benito R, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651–9.
Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS ONE. 2016;11(6):e0156728.
Lim C, Tsao M, Le L, Shepherd F, Feld R, Burkes R, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015;26(7):1415–21.
McKeage M, Elwood M, Tin ST, Khwaounjoo P, Aye P, Li A, et al. EGFR mutation testing of non-squamous NSCLC: impact and uptake during implementation of testing guidelines in a population-based registry cohort from northern New Zealand. Target Oncol. 2017;12(5):663–75.
Sandelin M, Berglund A, Sundstrom M, Micke P, Ekman S, Bergqvist M, et al. Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome. Anticancer Res. 2015;35(7):3979–85.
Shen C, Kehl KL, Zhao B, Simon GR, Zhou S, Giordano SH. Utilization patterns and trends in epidermal growth factor receptor (EGFR) mutation testing among patients with newly diagnosed metastatic lung cancer. Clin Lung Cancer. 2017;18(4):e233–e241241.
Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10(3):438–45.
Pan IW, Mallick R, Dhanda R, Nadler E. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. Lung Cancer. 2013;82(3):469–76.
Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, et al. EGFR mutation testing of lung cancer patients: experiences from Vestfold Hospital Trust. Acta Oncol. 2016;55(2):149–55.
Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gruning W, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013;3(4):e002560. https://doi.org/10.1136/bmjopen-2013-002560.
D’Angelo SP, Park B, Azzoli CG, Kris MG, Rusch V, Ladanyi M, et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg. 2011;141(2):476–80.
Ellis PM, Verma S, Sehdev S, Younus J, Leighl NB. Challenges to implementation of an epidermal growth factor receptor testing strategy for non–small-cell lung cancer in a publicly funded health care system. J Thorac Oncol. 2013;8(9):1136–41.
Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, et al. How molecular understanding affects to prescribing patterns and clinical outcome of gefitinib in non-small cell lung cancer? 10 year experience of single institution. Cancer Res Treat. 2013;45(3):178–85.
Martin Martorell P, Huerta M, Compan Quilis A, Abellan R, Seda E, Blesa S, et al. Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish nonsquamous NSCLC patients. Clin Lung Cancer. 2017;18(6):e395–402.
Sequist L, Heist R, Shaw A, Fidias P, Rosovsky R, Temel J, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22(12):2616–24.
Shinde R, Cao X, Kothari S. Biopsy procedures and molecular testing utilization and related costs in patients with metastatic lung cancer. J Manag Care Spec Pharm. 2016;22(10):1194–203.
Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012;77(2):371–5.
Barlesi F, Mazieres J, Merlio J, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–26.
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.
University of Bern (CH). Strobe statement: strengthening the reporting of observational studies in epidemiology. 2009. https://www.strobe-statement.org/index.php?id=available-checklists. Accessed 8 Jul 2018.
Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
National Heart, Lung and Blood Institute (US). Study quality assessment tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 8 Jul 2018.
Sun JM, Rampal S, Lee G, Lee J, Choi YL, Parasuraman B, et al. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer. Lung Cancer. 2013;80(2):191–6.
Cheng Y, Wang Y, Zhao J, Liu Y, Gao H, Ma K, et al. Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: a multicenter, non-interventional study. Thoracic Cancer. 2018;9(11):1461–9.
Ess S, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, et al. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: a comprehensive evaluation of real world practices. Eur J Cancer Care. 2017;26(6):e12721.
Lee DH, Tsao M, Kambartel K, Isobe H, Huang M, Barrios CH, et al. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS ONE. 2018;13(8):e0202865.
Nadler E, Pavilack M, Clark J, Espirito J, Fernandes A. Biomarker testing rates in patients with advanced non-small cell lung cancer treated in the community. J Cancer Ther. 2019;10(12):971.
Palacio S, Pontes L, Prado E, Arshad J, Ali R, Piha T, et al. EGFR mutation testing: changing patterns of molecular testing in Brazil. Oncologist. 2019;24(4):e137–e141141.
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–933.
Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005;10(Suppl. 3):1–10.
Cheema P, Raphael S, El-Maraghi R, Li J, McClure R, Zibdawi L, et al. Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists. Curr Oncol. 2017;24(1):16–22.
Cheema PK, Menjak IB, Winterton-Perks Z, Raphael S, Cheng SY, Verma S, et al. Impact of reflex EGFR/ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. J Oncol Pract. 2016;13(2):e130–e138138.
Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(32):1–166.
Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study. Lung Cancer. 2017;113:37–44.
Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol. 2013;66(12):1065–9.
Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009;15(6):2076–84.
Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S. Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res. 2009;9(1):131.
Carbonnaux M, Souquet PJ, Meert AP, Scherpereel A, Peters M, Couraud S. Inequalities in lung cancer: a world of EGFR. Eur Respir J. 2016;47(5):1502–9.
Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39(2):366–72.
Lynch JA, Khoury MJ, Borzecki A, Cromwell J, Hayman LL, Ponte PR, et al. Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genet Med. 2013;15(8):630–8.
Batten LS, Winter HS, Hardie CL, Holdaway MA. Clinicians' views on introducing epidermal growth factor receptor testing in N ew Z ealand. Asia-Pacific J Clin Oncol. 2013;9(3):249–56.
Jeffreys M, Stevanovic V, Tobias M, Lewis C, Ellison-Loschmann L, Pearce N, et al. Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public Health. 2005;95(5):834–7.
Elwood JM, Aye PS, Tin ST. Increasing disadvantages in cancer survival in New Zealand compared to Australia, between 2000–05 and 2006–10. PLoS ONE. 2016;11(3):e0150734.
Tin ST, McKeage MJ, Khwaounjoo P, Thi AM, Elwood JM. Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: a population-based study in New Zealand. Cancer Epidemiol. 2018;57:24–322.
Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN guidelines insights: non-small cell lung cancer, version 5. J Natl Compr Cancer Netw. 2018;16(7):807–21.
Author information
Authors and Affiliations
Contributions
The study was conceptualised by STT, AMT and ME. The literature search, data analysis and the original draft were performed by AMT, STT, MM and ME. The manuscript was critically revised by MM, STT and AMT. All authors contributed to the review and editing of the final manuscript.
Corresponding author
Ethics declarations
Funding
This work was supported by the Health Research Council of New Zealand (Grant numbers 13/981, 15/087 and 19/450). Aye Myat Thi was supported by the New Zealand ASEAN scholarship to study a Master of Public Health at the University of Auckland. Sandar Tin Tin was supported by the Auckland Medical Research Foundation/Perpetual David and Cassie Anderson Postdoctoral Fellowship (Grant number 1315002) and Kelliher Charitable Trust Emerging Researcher Start-up Award (Grant number 1716002).
Conflict of interest
Aye Myat Thi, Sandar Tin Tin, Mark McKeage and J. Mark Elwood have no conflicts of interest that are directly relevant to the content of this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Thi, A.M., Tin Tin, S., McKeage, M. et al. Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. Targ Oncol 15, 279–299 (2020). https://doi.org/10.1007/s11523-020-00718-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-020-00718-w